Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sigma-Aldrich Acquires ChemNavigator to Provide Researchers with Chemical Compound Selection and Procurement Services

Published: Friday, August 07, 2009
Last Updated: Friday, August 07, 2009
Bookmark and Share
Deal combines ChemNavigator's database of chemical compounds and cheminformatics tools with chemical services of Sigma-Aldrich.

Sigma-Aldrich has announced the acquisition of cheminformatics company, ChemNavigator.com, Incorporated, a provider of discovery research informatics software tools used for design, selection and procurement of chemical compound libraries.

The acquisition links ChemNavigator's comprehensive suite of virtual screening and selection tools and searchable database of over 60 million compounds with Sigma-Aldrich's core strengths in chemical compound management, procurement and global distribution to accelerate discovery research programs.

Early in the drug discovery process, researchers work at the molecular level to perform structure activity relationship (SAR) studies, seeking molecular patterns that may exhibit enhanced biological activity against disease targets. This virtual discovery process typically leads to a selection of compounds that can be compiled into target libraries based upon the identified SARs and molecular designs. Target compounds must then be identified from among the millions of potentially available chemicals and procured for actual testing of their biological properties.

ChemNavigator provides medicinal, computational and synthetic chemists with a comprehensive set of virtual screening tools and products that allows them to channel their chemical designs toward sets of commercially available compounds.

The company's sourcing database, the iResearch Library™, contains millions of chemical products available for selection and purchase, ranging from drug-like compounds for testing in molecular screening to synthetic building blocks used in chemical synthesis.

The acquisition aligns the global procurement and distribution capabilities of Sigma-Aldrich's Discovery(CPR) service with ChemNavigator's front-end cheminformatics research tools. These newly combined capabilities will provide customers with the complete chemical discovery offer, from compound selection to delivery of custom packaged chemical building blocks and screening libraries ready for testing.

"ChemNavigator is well-recognized for its fast and efficient virtual discovery tools and for its extensive database of chemical compounds," said Dr. Ilya Koltover, Manager, Business Development, for Sigma-Aldrich. "This acquisition enables Sigma-Aldrich to provide the research community with an efficient, seamless discovery offer that extends from virtual selection to compound delivery."

"Joining Sigma-Aldrich brings ChemNavigator's database and cheminformatics tools to a broader scientific audience and will allow scientists to utilize the full potential of both companies' expertise to accelerate their research," said Scott Hutton, President and Chief Executive Officer, ChemNavigator.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sigma-Aldrich to Restructure Business into Three New Units
Sigma-Aldrich has provided the first details of a major restructuring that will align its organisation into three customer and market-focused business units.
Thursday, November 22, 2012
Sigma-Aldrich® Receives National Institutes of Health Funding for Cardiovascular Disease Research
Sigma® Life Science to analyze plasma samples from FHS in researching novel biomarkers for cardiovascular disease.
Monday, August 09, 2010
Sigma-Aldrich Signs Exclusive Agreement with IsoSciences to Distribute Isotopically Labeled Bioactive Compounds
Under the terms of the agreement, IsoSciences will be the exclusive provider to Aldrich for their stable isotope products listed in the agreement for metabolic research.
Friday, September 12, 2008
Scientific News
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
A Metabolic Twist that Drives Cancer Survival
A novel metabolic pathway that helps cancer cells thrive in conditions that are lethal to normal cells has been identified.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Living Off the Fat of the Land
Do cancer cells synthesize the parts for new cells or scavenge them from the environment?
Liver Disease, Obesity Linked
Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed.
Decoding Ties Between Vascular Disease, Alzheimer’s
NIH consortium uses big data, team science to uncover complex interplay of factors.
Gene Identified that May Worsen Cancer Outcome
Some patients with breast cancer, lung cancer and leukaemia seem to fare poorly after treatment because of the effects of a particular gene, a new study finds.
‘Big Data’ Drills Down Into Metabolic Details
Rice University bioengineers introduce efficient way to analyze, compare tissue-specific pathways.
New Approach to Curbing Cancer Cell Growth
Using a new approach, scientists at The Scripps Research Institute (TSRI) and collaborating institutions have discovered a novel drug candidate that could be used to treat certain types of breast cancer, lung cancer and melanoma.
New Drug Delivery Method for Pancreatic Cancer
UCLA researchers use nanoparticles to send chemotherapy drug directly to the tumor site, reducing damage to healthy tissues.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!